The first-line treatment of choice for patients with EGFR activating mutations NSCLC is based on EGFR tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib, erlotinib, afatinib, dacomitinib and osimertinib. Here, EGFR is linked to non-small cell lung carcinoma.